Latham & Watkins Advises on Oviva’s US$80 Million Series C

London emerging companies team represents lead investor in one of Europe’s largest health tech raises to date in 2021.

September 03, 2021

Latham & Watkins advised the lead investor on its Series C investment in Oviva, a health tech startup. Oviva’s US$80 million Series C funding brings its total raised to date to US$115 million.

Oviva combines expert advice from dietitians with digital tools to help people with conditions such as type 2 diabetes improve their health. Oviva will use the new capital to scale up its business.

The Latham team was led by London partner Mike Turner and associate Samantha Si.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.